Circassia Archives

News and Trends 26 Feb 2018

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to develop immunotherapies against against grass pollen, peanut and house dust mite allergies. After raising €9.4M…

February 26, 2018 - 3 minutesmins - By Alexander Burik

Circassia pharmaceuticals astrazeneca pulmonary disease

News and Trends 7 Sep 2017

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia has positive Phase III results from its respiratory pipeline, great news for the company after abandoning its allergy immunotherapies due to clinical failure. Circassia Pharmaceuticals, based in Oxford, has…

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Apr 2017

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials in which the placebo beat its allergy immunotherapy. Circassia Pharmaceuticals has released the results from…

April 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Circassia failure AstraZeneca deal cover

News and Trends 17 Mar 2017

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to acquire rights from two AstraZeneca products for pulmonary disease. Circassia could not beat the placebo…

March 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here's a list of medical fails in biotech…

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jul 2016

June was a Tough Month for European Biotech… #Fail

Abivax, Celyad, Circassia and Genticel - these are all European Biotechs that took a hit after failing key clinical trials in June. How are they doing now? Four different public…

July 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

circassia cat grass allergy toleromune spire

News and Trends 21 Jun 2016

Allergy Immunotherapy Knocked Out in Phase III by an ‘Overperforming Placebo’

Circassia's pipeline takes a major step back as its therapy for cat allergy gets disappointing results -- it had the same effect as the placebo. Stocks promptly sank by 65%. The…

June 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

circassia grass allergy peptide spire trial

News and Trends 31 May 2016

UK Immunotherapy against Grass Allergies moves on to Phase III Trials

Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This common type of allergy can significantly impact the life quality of patients. Circassia is based…

May 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 14 Aug 2015

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

Cash is floating into Biotech like never before, in the US as well as in Europe. And Woodford just announced he invested over 75% of the total money he raised,…

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Feb 2015

2014, the Biggest Year Ever for European Biotech IPOs

There is no need to say it: biotechnology is the latest trend. A worldwide bio-boom has shaken stock markets throughout 2014. For European start-ups, last year represented a remarkable step…

February 6, 2015 - 3 minutesmins - By Lourdes Riquelme

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering